Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The next steps for effective cancer immunotherapy and viral vaccines

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.17
Views: 672

Prof Peter Selby - St James University Hospital, Leeds, UK

Prof Selby speaks with ecancer at the ACP immunotherapy workshop about research goals which can guide development and implementation of checkpoint immunotherapies.

He discusses the potential of oncolytic virotherapy in delivering guided therapy in mouse models, and how further research is needed to deliver the benefits in survival of best-responders to more patients within responsive diseases, and improve prospects in so-far non-responsive indications

Related videos

follow us

NCRI 2018

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence